During the past decade, Clarkston Skin Research conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 11 clinical trials were completed, i.e. on average, 61.1% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 11 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clarkston Skin Research" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "LEO Pharma" with 3 trials sponsored, "Amgen" with 2 trials sponsored, "Concert Pharmaceuticals" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clarkston Skin Research" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "Instat Consulting, Inc." with 2 trials as a collaborator, "Paidion Research, Inc." with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "BioClinica, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Clarkston Skin Research" are "Atopic Dermatitis" (5 trials), "Alopecia Areata" (3 trials), "Actinic Keratosis" (1 trials), "Atopic Dermatitis Eczema" (1 trials) and "Chronic Spontaneous Urticaria" (1 trials). Many other conditions were trialed in "Clarkston Skin Research" in a lesser frequency.

Most popular intervention types in "Clarkston Skin Research" are "Drug" (11 trials), "Biological" (4 trials), "Other" (4 trials), "Combination Product" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Lebrikizumab" (2 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Clarkston Skin Research" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Clarkston Skin Research". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 12 completed trials in Clarkston Skin Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Clarkston Skin Research, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".